Other News To Note
Dec16
? AFFiRis GmbH, of Vienna, Austria, said it started preclinical development of a Parkinson’s disease vaccine, PD01, which can be used to target alpha-synuclein, a protein associated with the causes of the disease. The company said the Austrian Research Promotion Agency has provided funding for development of PD01. Upon successful preclinical development, AFFiRis anticipates starting [...]
